cART(TDF/AZT+3TC+LPV/r) — Competitive Intelligence Brief

cART(TDF/AZT+3TC+LPV/r) (cART(TDF/AZT+3TC+LPV/r)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor, Protease inhibitor, Nucleotide reverse transcriptase inhibitor. Area: Infectious Diseases.

phase 3 Nucleoside reverse transcriptase inhibitor, Protease inhibitor, Nucleotide reverse transcriptase inhibitor HIV reverse transcriptase, HIV protease Infectious Diseases Small molecule

Target snapshot

cART(TDF/AZT+3TC+LPV/r) (cART(TDF/AZT+3TC+LPV/r)) — Yongtao Sun, MD, PhD. cART(TDF/AZT+3TC+LPV/r) is a combination antiretroviral therapy that works by inhibiting the replication of HIV.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
cART(TDF/AZT+3TC+LPV/r) TARGET	cART(TDF/AZT+3TC+LPV/r)	Yongtao Sun, MD, PhD	phase 3	Nucleoside reverse transcriptase inhibitor, Protease inhibitor, Nucleotide reverse transcriptase inhibitor	HIV reverse transcriptase, HIV protease
Symtuza® (TAF/FTC/DRV/c)	Symtuza® (TAF/FTC/DRV/c)	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (NRTI/INSTI class with protease inhibitor)	HIV reverse transcriptase, HIV protease, CYP3A4
Standard-of-care Antiretroviral therapy	Standard-of-care Antiretroviral therapy	Medical Research Council	marketed	Antiretroviral combination therapy (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitors)	HIV reverse transcriptase, HIV protease, HIV integrase, HIV envelope glycoproteins (CCR5/CXCR4 co-receptors)
tenofovir + emtricitabine + atazanavir-ritonavir	tenofovir + emtricitabine + atazanavir-ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + PI/r)	HIV reverse transcriptase, HIV protease
First-line Antiretroviral Therapy	First-line Antiretroviral Therapy	UPECLIN HC FM Botucatu Unesp	marketed	Antiretroviral combination therapy (NRTI/NNRTI/PI/INSTI)	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen components)
Standard Triple	Standard Triple	University of Alberta	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease (depending on formulation)
Different HAART regimens	Different HAART regimens	Danish HIV Research Group	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen composition)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor, Protease inhibitor, Nucleotide reverse transcriptase inhibitor class)

1. Yongtao Sun, MD, PhD · 1 drug in this class